8-K current report · filed Aug 13, 2026

ADC Therapeutics SA (ADCT) 8-K Current Report: August 13, 2026

Item EX-99.1Item EX-99.2Item 2.02Item 7.01ADCT overview

Short answer

ADC Therapeutics SA (ADCT) filed an 8-K current report with the SEC on August 13, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure). Q2 and first-half 2026 financial results announced for periods ended June 30, 2026.

ADC Therapeutics SA 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 and first-half 2026 financial results announced for periods ended June 30, 2026
  • Full financial details and management commentary contained in Exhibit 99.1
  • Results update provides investors with the latest operating performance and financial-condition data

Item 7.01 · Regulation FD Disclosure

  • Investor presentation released August 13, 2026 under Regulation FD
  • Exhibit 99.2 contains the substantive company update for investors

Item EX-99.1 · Exhibit EX-99.1

  • Q2 product revenue $18.6M, up from $18.1M; growth driven by higher pricing rather than underlying volume
  • FDA raised substantial LOTIS-5 benefit-risk concerns tied to Grade 5 events and marginal benefit, delaying the full-approval path
  • LOTIS-7 enrollment completed at 100 patients, supporting potential ZYNLONTA-glofitamab expansion into 2L+ DLBCL
  • Workforce reduction approximately 17%, targeting annualized cost savings of approximately $10M after trial completions
  • Cash $219.1M at June 30, 2026, with runway expected into at least 2028; Q2 net loss $16.6M or $0.11 per share

Item EX-99.2 · Exhibit EX-99.2

  • LOTIS-5 met its primary PFS endpoint: HR 0.73, p=0.008, median PFS 6.14 vs 4.73 months
  • ZYNLONTA plus rituximab delivered higher CR rates, 40% vs 27%, and stronger 24-month CR durability, 48.5% vs 16.7%
  • FDA raised substantial benefit-risk concerns after Grade 5 events, weakening the case for full approval despite efficacy improvements
  • Safety burden was higher with ZYNLONTA plus rituximab: Grade 5 TEAEs 2.9% vs 1.0%, serious TEAEs 49.0% vs 34.5%
  • Regulatory strategy and timing remain under evaluation, leaving earlier-line expansion and potential revenue growth uncertain

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other ADC Therapeutics SA 8-K filings

Get the next ADCT 8-K as it lands

Follow ADCT for push alerts, or ask the research agent what this filing means.